Endothelial Function in Patients With Pulmonary Arterial Hypertension
Hypertension, Pulmonary, Pulmonary Arterial Hypertension, Pathophysiology
About this trial
This is an interventional diagnostic trial for Hypertension, Pulmonary focused on measuring Pulmonary Arterial Hypertension, Prognostic factors, Signal transduction, Genetics
Eligibility Criteria
Inclusion Criteria:
- proven PH (by right heart catheterization, PAP >25 mmHg, within last 12 months)
- age >18 years
- Dana Point classification I or IV (all subgroups)
- declaration of consent
Exclusion Criteria:
- Pulmonary Hypertension not proven by right heart catheterization
- Eisenmenger's syndrome/reaction
- PH other than Dana Point I and IV
- alcohol or drug abuse
- non-compliance due to any cause (e.g. severe psychiatric disorder)
Sites / Locations
- Department of Respiratory Medicine, University Medical Center Hamburg-Eppendorf
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Active Comparator
Therapy-naive
Under therapy
Healthy controls
This group consists of patients with a newly diagnosed PH (Class I or IV). First blood sampling takes place before initiation of PH therapy (0 months), the following measurements will be performed after 3, 6, 9 and 12 months under specific therapy. Initiation of standard therapy is performed directly after baseline visit / study inclusion. No special study medication will be used. Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood Test
This group consists of patients under ERA monotherapy at timepoint of inclusion. Observation period is one year to detect intraindividual changes in endothelial dysfunction measured by L-arginine/NO-metabolites after 0, 3, 6, 9 and 12 months under investigation. Specific PAH therapy has been started prior to the study for medical reasons and will be continued throughout. Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood
This group consists of healthy individuals. Sex and age matching is intended. Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood